Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic ...

Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer Discovery Analysis Demonstrates Transformative Sensitivity of 95% ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ... Algorithm Based on Liquid Biosciences EMERGE Platform ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement ...

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ... Algorithm Based on Liquid Biosciences EMERGE Platform ...

BERKELEY, Calif. - Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company with a market capitalization of $16.47 million, has entered into an exclusive licensing agreement with ...

Pancreatic cancer starts in your pancreas, an organ that makes digestive juices and hormones, including insulin. There are two main types of pancreatic cancers—those that start in the exocrine gland ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.